**Supplementary Table 3. Unadjusted incidence of infection by organ class**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Etanercept | Infliximab | Adalimumab | Rituximab | Tocilizumab | Certolizumab |
| Number of patients | 8,630 | 4,908 | 7,818 | 5,101 | 2,174 | 1,446 |
| Follow-up time (years) | 15,314 | 8,829 | 13,071 | 5,910 | 1,963 | 1,685 |
|  | **Incidence by infection class per 100 patient years** | | | | | |
| Sepsis/Bacteraemia  (95% CI) | 0.15  (0.10, 0.23) | 0.14  (0.08, 0.24) | 0.16  (0.10, 0.25) | 0.44  (0.30, 0.64) | 0.31  (0.14, 0.68) | 0.12  (0.03, 0.47) |
| Respiratory  (95% CI) | 1.82  (1.61, 2.04) | 2.25  (1.96, 2.59) | 2.28  (2.04, 2.55) | 2.71  (2.32, 3.16) | 3.16  (2.46, 4.05) | 1.72  (1.20, 2.48) |
| Skin  (95% CI) | 1.31  (1.14, 1.51) | 1.21  (1.00, 1.46) | 0.89  (0.74, 1.06) | 0.90  (0.69, 1.17) | 1.38  (0.94, 2.01) | 0.42  (0.20, 0.87) |
| Gastrointestinal  (95% CI) | 0.50  (0.40, 0.63) | 0.51  (0.38, 0.68) | 0.38  (0.29, 0.50) | 0.58  (0.41, 0.81) | 0.76  (0.46, 1.27) | 0.18  (0.06, 0.55) |
| Bone/Joint  (95% CI) | 0.67  (0.55, 0.81) | 0.43  (0.31, 0.59) | 0.51  (0.40, 0.65) | 0.49  (0.34, 0.71) | 0.46  (0.24, 0.88) | 0.53  (0.28, 1.03) |
| Genitourinary  (95% CI) | 0.61  (0.50, 0.75) | 0.48  (0.35, 0.64) | 0.68  (0.55, 0.84) | 0.81  (0.61, 1.08) | 0.46  (0.24, 0.88) | 0.36  (0.16, 0.79) |
| Other Infection  (95% CI) | 0.36  (0.28, 0.47) | 0.25  (0.16, 0.38) | 0.41  (0.31, 0.53) | 0.32  (0.21, 0.50) | 0.41  (0.20, 0.81) | 0.30  (0.12, 0.71) |

CI – Confidence intervals